A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Study Name:
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Targeted Disease(s):
Lung Cancer

Study Dates:
February 5, 2021 - January 1, 2025

Type of Study:
Pre-Market

Study Location:
Nationwide

Lead Institution:
Advent Health Cancer Institute, Florida

Funding Source:
BeiGene

ClinicalTrails.gov Identifier:
NCT04746924

Conacts: 
BeiGene
Phone number  1-877-828-5568 
Email address    [email protected]

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Asthma Educator Institute
, | Dec 13, 2022